Loading organizations...
Key people at Hopen Life Science Ventures.
Hopen Life Science Ventures was founded in 2008 by Robert Hackenberg (Co-Founder & Managing Director).
Hopen Life Science Ventures is a venture capital firm investing in early- to mid-stage life science companies, primarily in the Midwest region, with headquarters in Grand Rapids, Michigan, and an additional office in Cleveland. The firm manages over $65 million across two funds, including the $40 million Hopen Life Science Fund II, leveraging its team's technical expertise to support young healthcare companies. It focuses on fueling growth in therapeutics for transplantation and diabetes, medical devices for heart repair and spine compression, and metabolic diseases. Its Fund I portfolio of seven companies has collectively raised over $110 million in syndicated investment. Notable portfolio companies include Tolera Therapeutics, Metabolic Solutions Development Company (MSDC), NeoChord, and Transcorp Spine, with Mark Olesnavage serving as a managing director. Hopen Life Science Ventures was founded in 2006 by a team with extensive experience in the life sciences sector.
Key people at Hopen Life Science Ventures.
Hopen Life Science Ventures was founded in 2008 by Robert Hackenberg (Co-Founder & Managing Director).
Hopen Life Science Ventures has 6 tracked investments across 5 companies. The latest tracked deal is $30.0M Series D in Delphinus Medical Technologies in September 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2022 | Delphinus Medical Technologies | $30.0M Series D | — | Beringea, Galen Partners, Paul Mccreadie, North Coast Technology Investors, Venture Investors, Waycross Ventures |
| Apr 11, 2017 | Cirius Therapeutics | $40.0M Series A | Daniel Estes, Nilesh Kumar | Adams Street Partners, Renaissance Venture Capital Fund |
| Sep 1, 2015 | Delphinus Medical Technologies | $40.0M Series C | John Neis | Beringea, Galen Partners, Arboretum Ventures, North Coast Technology Investors, Waycross Ventures |
| Apr 7, 2014 | Bjond | $3.3M Series A | Will Indest | TriStar Technology Ventures |
| Apr 1, 2014 | Sierra Oncology | $60.0M Series D | Albert CHA | Frazier Healthcare Partners, OrbiMed, Sofinnova Investments, VantagePoint Capital Partners, Amherst Fund, Donald Parfet, Alvin Vitangcol, Caxton Alternative Management, Grand Angels, Janus Henderson Investors, RA Capital Management, Sectoral Asset Management |
| Jul 1, 2011 | Trapelo Health | $7.0M Series B | Beringea, Koleman Karleski | Michigan Accelerator Fund |
